AZN•benzinga•
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
Summary
AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2025 by benzinga